Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292274 | 0.86 | AAK1 (0.39) | ALDH1A1TDP1BRD4LATS1AAK1 | |
| SCHEMBL292651 | 0.81 | MAPT (0.43) | MAPTALDH1A1TDP1LMNAHTT | |
| SCHEMBL27398698 | 0.80 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL291848 | 0.76 | SMN1; SMN2 (0.43) | ALDH1A1LMNASSTR4LATS1AAK1 | |
| SCHEMBL293665 | 0.72 | LATS1 (0.41) | MEN1KMT2AALDH1A1LMNASSTR4 | |
| SCHEMBL291652 | 0.72 | AKT1 (0.39) | BRD4SSTR4AAK1 | |
| SCHEMBL8292291 | 0.72 | KCNQ4 (0.48) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL293146 | 0.71 | L3MBTL1 (0.41) | ALDH1A1LMNASSTR4LATS1 | |
| SCHEMBL11933658 | 0.71 | P2RX7 (0.48) | ALDH1A1BRD4 | |
| SCHEMBL30882051 | 0.71 | SCN9A (0.50) | MEN1KMT2AALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | MAPT 4585/4885MEN1 869/4885KMT2A 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.